These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 24952194)

  • 21. [Proteomics and breast cancer: a search for novel diagnostic and theragnostic biomarkers].
    Gilabert M; Audebert S; Viens P; Borg JP; Bertucci F; Gonçalves A
    Bull Cancer; 2010 Mar; 97(3):321-39. PubMed ID: 20202919
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct Analysis of Leucine and Its Metabolites β-Hydroxy-β-methylbutyric Acid, α-Ketoisocaproic Acid, and α-Hydroxyisocaproic Acid in Human Breast Milk by Liquid Chromatography-Mass Spectrometry.
    Ehling S; Reddy TM
    J Agric Food Chem; 2015 Sep; 63(34):7567-73. PubMed ID: 26271627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative serum proteome analysis of human lymph node negative/positive invasive ductal carcinoma of the breast and benign breast disease controls via label-free semiquantitative shotgun technology.
    Hu X; Zhang Y; Zhang A; Li Y; Zhu Z; Shao Z; Zeng R; Xu LX
    OMICS; 2009 Aug; 13(4):291-300. PubMed ID: 19624269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proteomics of breast carcinoma.
    Somiari RI; Somiari S; Russell S; Shriver CD
    J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Feb; 815(1-2):215-25. PubMed ID: 15652811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) of human milk to identify dysregulated proteins in breast cancer.
    Aslebagh R; Channaveerappa D; Arcaro KF; Darie CC
    Electrophoresis; 2018 May; ():. PubMed ID: 29756217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SELDI-TOF-MS: the proteomics and bioinformatics approaches in the diagnosis of breast cancer.
    Hu Y; Zhang S; Yu J; Liu J; Zheng S
    Breast; 2005 Aug; 14(4):250-5. PubMed ID: 16085230
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Matrix-assisted laser desorption/ionisation (MALDI) TOF analysis identifies serum angiotensin II concentrations as a strong predictor of all-cause and breast cancer (BCa)-specific mortality following breast surgery.
    Boccardo F; Rubagotti A; Nuzzo PV; Argellati F; Savarino G; Romano P; Damonte G; Rocco M; Profumo A
    Int J Cancer; 2015 Nov; 137(10):2394-402. PubMed ID: 25994113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proteomics approaches: new technologies and clinical applications in breast carcinomas.
    Hamrita B; Nasr HB; Chahed K; Chouchane L
    Gulf J Oncolog; 2011 Jan; (9):36-44. PubMed ID: 21177207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of serological proteomic methods to find biomarkers associated with breast cancer.
    Rui Z; Jian-Guo J; Yuan-Peng T; Hai P; Bing-Gen R
    Proteomics; 2003 Apr; 3(4):433-9. PubMed ID: 12687611
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biomarkers in the diagnosis of primary and recurrent breast cancer.
    Tang SS; Gui GP
    Biomark Med; 2012 Oct; 6(5):567-85. PubMed ID: 23075236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical proteomics in breast cancer: a review.
    Gast MC; Schellens JH; Beijnen JH
    Breast Cancer Res Treat; 2009 Jul; 116(1):17-29. PubMed ID: 19082706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer proteomics: developments in technology, clinical use and commercialization.
    Yeat NC; Lin C; Sager M; Lin J
    Expert Rev Proteomics; 2015 Aug; 12(4):391-405. PubMed ID: 26145529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteomics discovery of radioresistant cancer biomarkers for radiotherapy.
    Chang L; Graham P; Hao J; Bucci J; Malouf D; Gillatt D; Li Y
    Cancer Lett; 2015 Dec; 369(2):289-97. PubMed ID: 26427840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-performance metabolic marker assessment in breast cancer tissue by mass spectrometry.
    Mimmi MC; Picotti P; Corazza A; Betto E; Pucillo CE; Cesaratto L; Cedolini C; Londero V; Zuiani C; Bazzocchi M; Esposito G
    Clin Chem Lab Med; 2011 Feb; 49(2):317-24. PubMed ID: 21143022
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative tissue proteomic investigation of invasive ductal carcinoma of breast with luminal B HER2 positive and HER2 enriched subtypes towards potential diagnostic and therapeutic biomarkers.
    Pendharkar N; Gajbhiye A; Taunk K; RoyChoudhury S; Dhali S; Seal S; Mane A; Abhang S; Santra MK; Chaudhury K; Rapole S
    J Proteomics; 2016 Jan; 132():112-30. PubMed ID: 26642762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breast cancer classification by proteomic technologies: current state of knowledge.
    Lam SW; Jimenez CR; Boven E
    Cancer Treat Rev; 2014 Feb; 40(1):129-38. PubMed ID: 23891266
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A proteomic approach to investigate potential biomarkers directed against membrane-associated breast cancer proteins.
    Canelle L; Bousquet J; Pionneau C; Hardouin J; Choquet-Kastylevsky G; Joubert-Caron R; Caron M
    Electrophoresis; 2006 Apr; 27(8):1609-16. PubMed ID: 16550497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mass spectrometry based proteomics profiling as diagnostic tool in oncology: current status and future perspective.
    Findeisen P; Neumaier M
    Clin Chem Lab Med; 2009; 47(6):666-84. PubMed ID: 19445650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Breast cancer diagnosis from proteomic mass spectrometry data: a comparative evaluation.
    Hand DJ
    Stat Appl Genet Mol Biol; 2008; 7(2):Article15. PubMed ID: 19120032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Challenges to developing proteomic-based breast cancer diagnostics.
    Drake RR; Cazares LH; Jones EE; Fuller TW; Semmes OJ; Laronga C
    OMICS; 2011 May; 15(5):251-9. PubMed ID: 21332380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.